Buy Recommendation: EyePoint Pharmaceuticals’ Promising Outlook with EYP-1901 for Diabetic Retinopathy and AMD

1d ago, source:

Analyst Graig Suvannavejh of Mizuho Securities reiterated a Buy rating on EyePoint Pharmaceuticals (EYPT – Research Report), retaining ...

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

4d ago, source:

WATERTOWN, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, ...

EyePoint Pharmaceuticals, Inc. (EYPT)

4d ago, source: Yahoo Finance

- Charles Wykoff, M.D., Ph.D. joins Carl Regillo, M.D., FACS as co-chair of Scientific Advisory Board – - Usha Chakravarthy, M.B.B.S, PhD., Allen Ho, M.D. FACS ...

EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer

1mon ago, source: Business Insider

March 04, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with ...

EyePoint Pharmaceuticals Stock (NASDAQ:EYPT), Analyst Ratings, Price Targets, Predictions

1mon ago, source: Benzinga.com

$20.67 30.62% HC Wainwright & Co.

Critical Insights From EyePoint Pharmaceuticals Analyst Ratings: What You Need To Know

1mon ago, source: Benzinga.com

Stay informed and make well-informed decisions with our Ratings Table. EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products ...

EyePoint Pharmaceuticals Inc EYPT

1mon ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer

1mon ago, source: Finanznachrichten

March 04, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with ...

EyePoint Pharmaceuticals Inc.

23d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...